INO Deadline: INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit

Core Viewpoint - Inovio Pharmaceuticals, Inc. is facing a securities fraud lawsuit, with a lead plaintiff deadline set for April 7, 2026, for investors who purchased securities during the specified class period from October 10, 2023, to December 26, 2025 [1]. Group 1: Lawsuit Details - The lawsuit alleges that during the class period, Inovio made false and misleading statements regarding the manufacturing of its CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [5]. - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5]. - The lawsuit asserts that when the true details became public, investors suffered damages due to the misleading statements made by the defendants [5]. Group 2: Class Action Participation - Investors who purchased Inovio securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - A class has not yet been certified, meaning investors are not represented by counsel unless they retain one, and participation as a lead plaintiff is not necessary for potential recovery [7].